Updates in Cardiology
FDA ( Food and Drug Administration )
FDA: no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesartan in patients with diabetes
The FDA ( Food and Drug Administration ) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesart …
News
Patients with bicuspid aortic valve without Marfan syndrome: identification of fibrillin 1 gene mutations
Bicuspid aortic valve ( BAV ) is the most frequent congenital heart disease with frequent involvement in thoracic aortic dilatation, aneurysm and dissection. Although BAV and Marfan syndrome ( MFS ) share some clinical features, and some MFS … more
Angiotensin receptor neprilysin inhibitors: independence of the blood pressure lowering effect and efficacy of the LCZ696, in patients with heart failure with preserved ejection fraction
The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New York Heart Association ( NYHA ) class in … more
Anticoagulation with Warfarin offers a net benefit in patients with atrial fibrillation and renal failure
A study has evaluated if Warfarin provides net benefit in patients with atrial fibrillation and renal failure. The data in this retrospective study of 283,969 patients with atrial fibrillation were obtained by analysis of health care databases in … more